HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Panel Backs Split-Tablet Stability Test, With Reservations

This article was originally published in The Tan Sheet

Executive Summary

FDA wants manufacturers to demonstrate split tablets are safe under ideal conditions. Panelists concur, but wonder how useful the data will be to consumers. FDA convened the meeting to consider its 2011 draft guidance, which proposed designating on packaging whether tablets meet scoring guidelines.

You may also be interested in...



FDA’s Top-Four Tablet Scoring Concerns To Get Advisory Committee Review

The Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will vote on some aspects of FDA’s draft scoring guidance, potentially giving generic industry a clue of future agency actions.

Regulatory News In Brief

FDA issues guidance on splitting tablets

Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees

However, user fee carryover balances will not last forever and service cuts are inevitable if a shutdown lingers for several weeks.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel